TY - JOUR
T1 - P-tau/aβ42 and aβ42/40 ratios in csf are equally predictive of amyloid pet status
AU - Campbell, Michelle R.
AU - Ashrafzadeh-Kian, Susan
AU - Petersen, Ronald C.
AU - Mielke, Michelle M.
AU - Syrjanen, Jeremy A.
AU - van Harten, Argonde C.
AU - Lowe, Val J.
AU - Jack, Clifford R.
AU - Bornhorst, Joshua A.
AU - Algeciras-Schimnich, Alicia
N1 - Publisher Copyright:
© 2021 The Authors.
PY - 2021
Y1 - 2021
N2 - Introduction: Measurement of amyloid beta (Aβ40 and Aβ42) and tau (phosphorylated tau [p-tau] and total tau [t-tau]) in cerebrospinal fluid (CSF) can be utilized to differentiate clinical and preclinical Alzheimer’s disease dementia (AD) from other neurodegenerative processes. Methods: CSF biomarkers were measured in 150 participants from the Mayo Clinic Study of Aging and the Alzheimer’s Disease Research Center. P-tau/Aβ42 (Roche Elecsys, Fujirebio LUMIPULSE) and Aβ42/40 (Fujirebio LUMIPULSE) ratios were compared to one another and to amyloid positron emission tomography (PET) classification. Results: Strong correlation was observed between LUMIPULSE p-tau/Aβ42 and Aβ42/40, as well as Elecsys and LUMIPULSE p-tau/Aβ42 and Aβ42/40 (Spearman’s ρ = –0.827, –0.858, and 0.960, respectively). Concordance between LUMIPULSE p-tau/Aβ42 and Aβ42/40 was 96% and between Elecsys p-tau/Aβ42 and both LUMIPULSE ratios was 97%. All ratios had > 94% overall, positive, and negative percent agreement with amyloid PET classification. Discussion: These data suggest that p-tau/Aβ42 and Aβ42/40 ratios provide similar clinical information in the assessment of amyloid pathology.
AB - Introduction: Measurement of amyloid beta (Aβ40 and Aβ42) and tau (phosphorylated tau [p-tau] and total tau [t-tau]) in cerebrospinal fluid (CSF) can be utilized to differentiate clinical and preclinical Alzheimer’s disease dementia (AD) from other neurodegenerative processes. Methods: CSF biomarkers were measured in 150 participants from the Mayo Clinic Study of Aging and the Alzheimer’s Disease Research Center. P-tau/Aβ42 (Roche Elecsys, Fujirebio LUMIPULSE) and Aβ42/40 (Fujirebio LUMIPULSE) ratios were compared to one another and to amyloid positron emission tomography (PET) classification. Results: Strong correlation was observed between LUMIPULSE p-tau/Aβ42 and Aβ42/40, as well as Elecsys and LUMIPULSE p-tau/Aβ42 and Aβ42/40 (Spearman’s ρ = –0.827, –0.858, and 0.960, respectively). Concordance between LUMIPULSE p-tau/Aβ42 and Aβ42/40 was 96% and between Elecsys p-tau/Aβ42 and both LUMIPULSE ratios was 97%. All ratios had > 94% overall, positive, and negative percent agreement with amyloid PET classification. Discussion: These data suggest that p-tau/Aβ42 and Aβ42/40 ratios provide similar clinical information in the assessment of amyloid pathology.
KW - Alzheimer’s disease dementia
KW - Amyloid beta 42/40
KW - Amyloid positron emission tomography
KW - Cerebrospinal fluid biomarkers
KW - Elecsys
KW - Immunoassay
KW - LUMIPULSE
KW - P-tau/Aβ42
UR - http://www.scopus.com/inward/record.url?scp=85108220902&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108220902&partnerID=8YFLogxK
U2 - 10.1002/dad2.12190
DO - 10.1002/dad2.12190
M3 - Article
AN - SCOPUS:85108220902
SN - 2352-8729
VL - 13
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
IS - 1
M1 - e12190
ER -